Table 1

Multivariate analysis of clinicopathological parameters and HSPC111 expression in two breast cancer cohorts

Variable

Hazard ratio (95% confidence interval)

P

Uppsala cohort

Tumor size > 20 mm

3.20 (1.65 to 6.21)

0.0006

Lymph node positive

3.13 (1.79 to 5.46)

< 0.0001

HER2 high expression

1.82 (1.02 to 3.27)

0.0444

HSPC111 high expression

2.29 (1.30 to 4.03)

0.0043

HSPC111 high expression

2.51 (1.43 to 4.41)

0.0014

MYC high expression

1.89 (1.06 to 3.36)

0.0305

NKI cohort

Tumour size > 20 mm

1.90 (1.10 to 3.28)

0.0223

Tumour grade > 2

2.04 (1.22 to 3.44)

0.0070

ER positive

0.67 (0.38 to 1.18)

0.1636

PR positive

0.56 (0.32 to 1.00)

0.0490

HER2 high expression

1.46 (0.87 to 2.43)

0.1493

HSPC111 high expression

1.29 (0.79 to 2.12)

0.3074

HSPC111 high expression

1.89 (1.17 to 3.08)

0.0097

MYC high expression

1.83 (1.14 to 2.93)

0.0118

NKI, Nederlands Kanker Instituut.

Butt et al. Breast Cancer Research 2008 10:R28   doi:10.1186/bcr1985